Search

Your search keyword '"SCHMELING, HEINRIKE"' showing total 98 results
Start Over Author "SCHMELING, HEINRIKE"
98 results on '"SCHMELING, HEINRIKE"'

51. Feasibility and safety of a 6-month exercise program to increase bone and muscle strength in children with juvenile idiopathic arthritis

Author

Houghton, Kristin M., Macdonald, Heather M., McKay, Heather A., Guzman, Jaime, Duffy, Ciarán, Tucker, Lori, Berard, Roberta, Boire, Gilles, Bruns, Alessandra, Campillo, Sarah, Chédeville, Gaëlle, Dancey, Paul, Ellsworth, Janet, Feldman, Debbie, Huber, Adam, Johnson, Nicole, Jurencak, Roman, Leblanc, Claire, Levy, Deborah, Miettunen, Paivi, Morishita, Kimberly, Ramsey, Suzanne, Rosenberg, Alan, Roth, Johannes, Rumsey, Dax, Schmeling, Heinrike, Scuccimarri, Rosie, Shiff, Natalie, and Stringer, Elizabeth

Subjects
Male, lcsh:Diseases of the musculoskeletal system, Childhood arthritis, Arthritis, Radius bone, Cohort Studies, 0302 clinical medicine, Absorptiometry, Photon, Quality of life, Bone Density, Immunology and Allergy, 030212 general & internal medicine, Longitudinal Studies, Quantitative computed tomography, Child, medicine.diagnostic_test, lcsh:RJ1-570, Exercise Therapy, medicine.anatomical_structure, Treatment Outcome, Muscle, Female, medicine.symptom, Exercise prescription, Research Article, medicine.medical_specialty, Canada, Adolescent, Juvenile arthritis, 03 medical and health sciences, Rheumatology, Internal medicine, medicine, Humans, Muscle Strength, Bone, Exercise, 030203 arthritis & rheumatology, business.industry, Physical activity, Muscle weakness, lcsh:Pediatrics, medicine.disease, Arthritis, Juvenile, Pediatrics, Perinatology and Child Health, Physical therapy, Quality of Life, Feasibility Studies, Patient Compliance, lcsh:RC925-935, business, Tomography, X-Ray Computed
Abstract

Background Arthritis in childhood can be associated with muscle weakness around affected joints, low bone mass and low bone strength. Exercise is recognized as an important part of management of children with juvenile idiopathic arthritis (JIA) but the exercise prescription to best promote bone and muscle health is unknown. We therefore aimed to: 1. assess feasibility and safety of a 6-month home- and group-based exercise program for children with JIA; 2. estimate the effect of program participation on bone mass and strength, muscle function and clinical outcomes and 3. determine if any positive changes in bone and muscle outcomes are maintained 6 months later. Methods We recruited 24 children with JIA who were part of the Linking Exercise, Physical Activity and Pathophysiology in Childhood Arthritis (LEAP) study to participate in a 6-month home-based exercise program involving jumping and handgrip exercises, resistance training and one group exercise session per month. We assessed lumbar spine bone mass (dual energy X-ray absorptiometry), distal tibia and radius bone microarchitecture and strength (high-resolution peripheral quantitative computed tomography), muscle function (jumping mechanography, dynamometry) and clinical outcomes (joint assessment, function, health-related quality of life) at baseline, 6- and 12-months. Adherence was assessed using weekly activity logs. Results Thirteen children completed the 6-month intervention. Participants reported 9 adverse events and post-exercise pain was rare (0.4%). Fatigue improved, but there were no other sustained improvements in muscle, bone or clinical outcomes. Adherence to the exercise program was low (47%) and decreased over time. Conclusion Children with JIA safely participated in a home-based exercise program designed to enhance muscle and bone strength. Fatigue improved, which may in turn facilitate physical activity participation. Prescribed exercise posed adherence challenges and efforts are needed to address facilitators and barriers to participation in and adherence to exercise programs among children with JIA. Trial registration Data of the children with JIA are from the LEAP study (Canadian Institutes of Health Research (CIHR; GRANT# 107535). http://www.leapjia.com/ Electronic supplementary material The online version of this article (10.1186/s12969-018-0283-4) contains supplementary material, which is available to authorized users.

Published
2018

52. THU0516 LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

Author

Benedetti, Fabrizio De, primary, Ruperto, Nicolino, additional, Ramanan, Athimalaipet, additional, Cuttica, Ruben, additional, Weiss, Jennifer E., additional, Henrickson, Michael, additional, Schmeling, Heinrike, additional, Anton, Jordi, additional, Minden, Kirsten, additional, Horneff, Gerd, additional, Gámir, Maria Luz Gámir, additional, Hufnagel, Markus, additional, Douglass, Wendy, additional, Wells, Chris, additional, Mallalieu, Navita L., additional, Martini, Alberto, additional, Lovell, Daniel J, additional, and Brunner, Hermine, additional

Published
2019
Full Text
View/download PDF

53. FRI0572 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL

Author

Ruperto, Nicolino, primary, Chen, Chen, additional, Martini, Alberto, additional, Espada, Graciela, additional, Joos, Rik, additional, Akikusa, Jonathan, additional, Chaitow, Jeffrey, additional, Maria Luz, Gámir Gámir, additional, Kimura, Yukiko, additional, Rietschel, Christoph, additional, Siri, Daniel, additional, Smolewska, Elzbieta, additional, Schmeling, Heinrike, additional, Brown, Diane, additional, Benedetti, Fabrizio De, additional, Lovell, Daniel J., additional, Huang, Bin, additional, and Brunner, Hermine, additional

Published
2019
Full Text
View/download PDF

54. SAT0613 CHANGING TREATMENTS AND OUTCOMES FOR JUVENILE IDIOPATHIC ARTHRITIS: INITIAL FINDINGS FROM A NEW CANADIAN INCEPTION COHORT

Author

Guzman, Jaime, primary, Batthish, Michelle, additional, Berard, Roberta, additional, Bolaria, Roxana, additional, Cabral, David, additional, Chédeville, Gaëlle, additional, Duffy, Ciaran, additional, Gerhold, Kerstin, additional, Gerschman, Tommy, additional, Huber, Adam, additional, Proulx-Gauthier, Jean-Philippe, additional, Rosenberg, Alan, additional, Rumsey, Dax, additional, Schmeling, Heinrike, additional, Shiff, Natalie, additional, Soon, Gordon, additional, and Tucker, Lori, additional

Published
2019
Full Text
View/download PDF

56. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis

Author

Amlani, Adam, primary, Choi, May Y., additional, Tarnopolsky, Mark, additional, Brady, Lauren, additional, Clarke, Ann E., additional, Garcia-De La Torre, Ignacio, additional, Mahler, Michael, additional, Schmeling, Heinrike, additional, Barber, Claire E., additional, Jung, Michelle, additional, and Fritzler, Marvin J., additional

Published
2019
Full Text
View/download PDF

57. 170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis

Author

Ramanan, Athimalaipet V, primary, Brunner, Hermine I, additional, Ruperto, Nicola, additional, Martini, Alberto, additional, Cuttica, Rubén J, additional, Weiss, Jennifer E, additional, Henrickson, Michael, additional, Schmeling, Heinrike, additional, Antón, Jordi, additional, Minden, Kirsten, additional, Horneff, Gerd, additional, Gámir-Gámir, María Luz, additional, Hufnagel, Markus, additional, Douglass, Wendy, additional, Wells, Chris, additional, Wimalasundera, Sunethra, additional, Mallalieu, Navita L, additional, Lovell, Daniel J, additional, and Benedetti, Fabrizio De, additional

Published
2019
Full Text
View/download PDF

58. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study.

Author

Grazziotin, Luiza R., Currie, Gillian, Twilt, Marinka, Ijzerman, Maarten J., Kip, Michelle M. A., Koffijberg, Hendrik, Benseler, Susanne M., Swart, Joost F., Vastert, Sebastiaan J., Wulffraat, Nico M., Yeung, Rae S. M., Johnson, Nicole, Luca, Nadia J., Miettunen, Paivi M., Schmeling, Heinrike, and Marshall, Deborah A.

Subjects
JUVENILE idiopathic arthritis, PEDIATRIC clinics, BIOTHERAPY, COHORT analysis, DISTRIBUTION costs, RHEUMATISM, RHEUMATOLOGISTS
Abstract

Introduction: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease, whose multifaceted care path can lead to significant expenditure for the healthcare system. We aim to assess the real-world healthcare resource use (HCRU) and associated cost for children with JIA in a single center in Canada. Methods: A single-center consecutive cohort of newly diagnosed patients with JIA attending the pediatric rheumatology clinic from 2011 to 2019 was identified using an administrative data algorithm and electronic medical charts. HCRU was estimated from six administrative health databases that included hospital admissions, emergency, outpatient care, practitioners' visits, medication, and laboratory and imaging tests. Costs were assigned using appropriate sources. We reported the yearly overall and JIA-associated HCRU and costs 5 years prior to and 6 years after the first visit to the pediatric rheumatologist. The Zhao and Tian estimator was used to calculate cumulative mean costs over a 6-year timeframe. Results were stratified by disease subtype. Results: A total of 389 patients were identified. The yearly total overall mean costs per patient ranged between $804 and $4460 during the 5 years prior to the first visit to the pediatric rheumatologist and $8529 and $10,651 for the 6 years after. Medication cost, driven by use of biologic therapies, and outpatient visits were the greatest contributor to the total cost. The overall cumulative mean cost for 6 years of care was $48,649 per patient, while the JIA-associated cumulative mean cost was $26,820 per patient. During the first year of rheumatology care, systemic onset JIA had the highest cumulative mean overall cost, while oligoarticular JIA had the lowest cumulative mean cost. Conclusion: The care pathway for children with JIA can be expensive, and complex—and varies by JIA subtype. Although the yearly total mean cost per patient was constant, the distribution of costs changes over time with the introduction of biologic therapies later in the care pathway. This study provides a better understanding of the JIA costs profile and can help inform future economic studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

59. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.

Author

Brunner, Hermine I., Chen, Chen, Bovis, Francesca, De Benedetti, Fabrizio, Espada, Graciela, Joos, Rik, Akikusa, Jonathan, Chaitow, Jeffrey, Boteanu, Alina Lucica, Kimura, Yukiko, Rietschel, Christoph, Siri, Daniel, Smolewska, Elzbieta, Schmeling, Heinrike, Brown, Diane E., Martini, Alberto, Lovell, Daniel J., Huang, Bin, Ruperto, Nicolino, and Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

Subjects
QUALITY of life, TOCILIZUMAB, IMMUNOSUPPRESSIVE agents, JUVENILE idiopathic arthritis, RHEUMATISM in children
Abstract

Objective: To evaluate changes in health-related quality of life (HRQoL) and disability in children with systemic juvenile idiopathic arthritis (JIA) or polyarticular JIA treated with tocilizumab.Methods: Secondary analyses of two double-blind, placebo-controlled trials of intravenous tocilizumab in children with active systemic JIA or polyarticular JIA were conducted. Patient-reported outcomes of disability (Childhood Health Assessment Questionnaire [C-HAQ]), HRQoL (Child Health Questionnaire Parent Form 50 [CHQ-P50], health concepts, physical summary score [CHQ-P50-PhS], psychosocial summary score [CHQ-P50-PsS]), pain, and well-being (100-mm visual analog scale [VAS]) were measured at weeks 0 and 12 for systemic JIA, weeks 16 and 40 for polyarticular JIA, and week 104 for both JIA subgroups.Results: The trial included 112 patients with systemic JIA and 188 patients with polyarticular JIA. In patients with polyarticular JIA, the mean ± SD C-HAQ score decreased from 1.39 ± 0.74 at baseline to 0.67 ± 0.65 at week 16 (P < 0.001). In patients with systemic JIA, the mean ± SD CHQ-P50-PhS improved more with tocilizumab therapy than with placebo at week 12 (7.3 ± 10.2 versus 2.4 ± 10.6) (P < 0.05). Almost all mean CHQ-P50 health concept scores, CHQ-P50-PsS, and CHQ-P50-PhS improved (P ≤ 0.002) by week 104 for patients with systemic JIA. Patients with polyarticular JIA and patients with systemic JIA showed significant reductions in disability (mean ± SD C-HAQ scores of -1.09 ± 0.71 and -1.17 ± 0.80, respectively), improvements in well-being (mean ± SD well-being VAS scores of -43.76 ± 26.61 and -51.53 ± 23.57, respectively), and decreases in pain (mean ± SD pain VAS scores of -41.56 ± 31.06 and -51.26 ± 26.79, respectively) (P < 0.001); in patients with polyarticular JIA and patients with systemic JIA who were treated with tocilizumab, 92.9% of polyarticular JIA patients and 96.8% of systemic JIA patients reported no more than minimal pain (a score of ≤35 mm on the VAS) at week 104.Conclusion: Tocilizumab treatment was associated with significantly reduced disability and pain and improved HRQoL in patients with systemic JIA and polyarticular JIA. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

60. Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis

Author

Oen, Kiem, Guzman, Jaime, Dufault, Brenden, Tucker, Lori B, Shiff, Natalie J, Duffy, Karen Watanabe, Lee, Jennifer J Y, Feldman, Brian M, Berard, Roberta A, Dancey, Paul, Huber, Adam M, Scuccimarri, Rosie, Cabral, David A, Morishita, Kimberly A, Ramsey, Suzanne E, Rosenberg, Alan M, Boire, Gilles, Benseler, Susanne M, Lang, Bianca, Houghton, Kristin, Miettunen, Paivi M, Chédeville, Gaëlle, Levy, Deborah M, Bruns, Alessandra, Schmeling, Heinrike, Haddad, Elie, Yeung, Rae S M, Duffy, Ciarán M, and The Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) investigators

Subjects
Male, Pediatrics, Time Factors, Arthritis, Child Behavior, Disability Evaluation, 0302 clinical medicine, Child Development, Quality of life, Surveys and Questionnaires, Medicine, longitudinal studies, Longitudinal Studies, 030212 general & internal medicine, Child, Pain Measurement, Oligoarthritis, adolescent development, Age Factors, Prognosis, humanities, female, arthritis, Predictive value of tests, Child, Preschool, Cohort, Female, Polyarthritis, medicine.medical_specialty, age factors, Canada, Adolescent, disability evaluation, adolescent behavior, pain measurement, preschool, 03 medical and health sciences, Rheumatology, Predictive Value of Tests, Humans, Survival analysis, 030203 arthritis & rheumatology, business.industry, Adolescent Development, medicine.disease, Child development, Arthritis, Juvenile, juvenile, quality of life, Adolescent Behavior, Quality of Life, business
Abstract

Objective To describe changes in health-related quality of life (HRQoL) over time in children with juvenile idiopathic arthritis (JIA), relative to other outcomes, and to identify predictors of unfavorable HRQoL trajectories. Methods Children with JIA in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) cohort were included. The Juvenile Arthritis Quality of Life Questionnaire (JAQQ, a standardized instrument), health-related Quality of My Life (HRQoML, an instrument based on personal valuations), and JIA core variables were completed serially. Analyses included median values, Kaplan-Meier survival curves, and latent trajectory analysis. Results A total of 1,249 patients enrolled at a median of 0.5 months after diagnosis were followed for a median of 34.2 months. The degree of initial HRQoL impairment and probabilities of reaching the best possible HRQoL scores varied across JIA categories (best for oligoarthritis, worst for rheumatoid factor–positive polyarthritis). Median times to attain best possible HRQoL scores (JAQQ 59.3 months, HRQoML 34.5 months), lagged behind those for disease activity, pain, and disability measures. Most patients followed trajectories with minimal or mild impairment; however, 7.6% and 13.8% of patients, respectively, followed JAQQ and HRQoML trajectories with persistent major impairment in HRQoL. JIA category, aboriginal ethnicity, and baseline disease activity measures distinguished between membership in trajectories with major and minimal impairments. Conclusion Improvement in HRQoL is slower than for disease activity, pain, and disability. Improvement of a measure based on respondents’ preferences (HRQoML) is more rapid than that of a standardized measure (JAQQ). Higher disease activity at diagnosis heralds an unfavorable HRQoL trajectory.

Published
2018

61. Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America.

Author

Sabbagh, Sara E, Neely, Jessica, Chow, Albert, DeGuzman, Marietta, Lai, Jamie, Lvovich, Svetlana, McGrath, Tara, Pereira, Maria, Pinal-Fernandez, Iago, Roberts, Jordan, Rouster-Stevens, Kelly, Schmeling, Heinrike, Sura, Anjali, Tarshish, Gabriel, Tucker, Lori, Rider, Lisa G, Kim, Susan, and Group, for the CARRA JDM Workgroup and the Childhood Myositis Heterogeneity Study

Subjects
AUTOANTIBODIES, COMPARATIVE studies, CONFIDENCE intervals, INTERSTITIAL lung diseases, MYOSITIS, PNEUMOCYSTIS pneumonia, QUESTIONNAIRES, PHENOTYPES, ODDS ratio, SKIN ulcers, DISEASE risk factors
Abstract

Objectives Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, there are few studies examining PJP in juvenile myositis [juvenile idiopathic inflammatory myopathy (JIIM)]. The purpose of this study was to determine the risk factors and clinical phenotypes associated with PJP in JIIM. Methods An research electronic data capture (REDCap) questionnaire regarding myositis features, disease course, medications and PJP infection characteristics was completed by treating physicians for 13 JIIM patients who developed PJP (PJP+) from the USA and Canada. Myositis features and medications were compared with 147 JIIM patients without PJP (PJP–) from similar geographic regions who enrolled in National Institutes of Health natural history studies. Results PJP+ patients were more often of Asian ancestry than PJP– patients [odds ratio (OR) 8.7; 95% CI 1.3, 57.9]. Anti- melanoma differentiation associated protein 5 (MDA5) autoantibodies (OR 12.5; 95% CI 3.0, 52.4), digital infarcts (OR 43.8; 95% CI 4.2, 460.2), skin ulcerations (OR 12.0; 95% CI 3.5, 41.2) and interstitial lung disease (OR 10.6; 95% CI 2.1, 53.9) were more frequent in PJP+ patients. Before PJP diagnosis, patients more frequently received pulse steroids, rituximab and more immunosuppressive therapy compared with PJP– patients. Seven PJP+ patients were admitted to the intensive care unit and four patients died due to PJP or its complications. Conclusions PJP is a severe infection in JIIM that can be associated with mortality. Having PJP was associated with more immunosuppressive therapy, anti-MDA5 autoantibodies, Asian race and certain clinical features, including digital infarcts, cutaneous ulcerations and interstitial lung disease. Prophylaxis for PJP should be considered in juvenile myositis patients with these features. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

62. The iCanCope pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial.

Author

Lalloo, Chitra, Harris, Lauren R, Hundert, Amos S, Berard, Roberta, Cafazzo, Joseph, Connelly, Mark, Feldman, Brian M, Houghton, Kristin, Huber, Adam, Laxer, Ronald M, Luca, Nadia, Schmeling, Heinrike, Spiegel, Lynn, Tucker, Lori B, Pham, Quynh, Davies-Chalmers, Cleo C, and Stinson, Jennifer N

Subjects
PSYCHOLOGICAL adaptation in adolescence, PATIENT compliance, QUALITY of life, JUVENILE idiopathic arthritis, HEALTH self-care, SOCIAL support, RANDOMIZED controlled trials, TREATMENT effectiveness, HUMAN services programs, SMARTPHONES, MOBILE apps
Abstract

Objectives To evaluate the feasibility and preliminary effectiveness of iCanCope with Pain (iCanCope), a smartphone-based pain self-management program, in adolescents with JIA. iCanCope featured symptom tracking, goal-setting, pain coping skills and social support. Methods A two-arm pilot randomized controlled trial was used to evaluate the iCanCope app compared with a version with symptom tracking only. Primary (feasibility) outcomes were: participant accrual/attrition rates, success of app deployment, acceptability and adherence. Secondary (preliminary effectiveness) outcomes were: pain intensity, pain-related activity limitations and health-related quality of life. Outcomes were assessed at baseline and 8 weeks. Adherence was defined as the proportion of completed symptom reports: 'low' (≤24%); 'low-moderate' (25–49%); 'high-moderate' (50–75%); or 'high' (76–100%). Linear mixed models were applied for preliminary effectiveness analyses as per intention-to-treat. Results Adolescents (N  = 60) were recruited from three paediatric rheumatology centres. Rates of accrual and attrition were 82 and 13%, respectively. Both apps were deployed with high success (over 85%) and were rated as highly acceptable. Adherence was similar for both groups, with most participants demonstrating moderate-to-high adherence. Both groups exhibited a clinically meaningful reduction in pain intensity (≥1 point) that did not statistically differ between groups. There were no significant changes in activity limitations or health-related quality of life. Conclusion The iCanCope pilot randomized controlled trial was feasible to implement in a paediatric rheumatology setting. Both apps were deployed successfully, with high acceptability, and were associated with moderate-to-high adherence. Preliminary reductions in pain intensity warrant a future trial to evaluate effectiveness of iCanCope in improving health outcomes in adolescents with JIA. Trial registration ClinicalTrials.gov identifier: NCT02764346. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

63. A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry.

Author

Batthish, Michelle, Berard, Roberta, Cabral, David, Bolaria, Roxana, Chédeville, Gaëlle, Duffy, Ciaran, Gerhold, Kerstin, Gerschman, Tommy, Huber, Adam, Proulx-Gauthier, Jean-Philippe, Rosenberg, Alan, Rumsey, Dax, Schmeling, Heinrike, Shiff, Natalie, Soon, Gordon, Bruns, Alessandra, Tucker, Lori, Guzman, Jaime, and Investigators, for The Canadian Alliance of Pediatric Rheumatology

Subjects
BIOTHERAPY, REPORTING of diseases, DRUG side effects, JUVENILE idiopathic arthritis, TREATMENT effectiveness, CONTENT mining, KAPLAN-Meier estimator
Abstract

Objectives The aim was to describe the design, methods and initial findings of a new Canadian inception cohort of children with JIA, The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry. Methods The CAPRI JIA Registry was started in 2017 to collect information prospectively on children enrolled within 3 months of JIA diagnosis across Canada. The registry has a non-traditional modular design, with no artificially set times for registry visits to occur, streamlined multi-method data collection that requires 2–4 min per visit, and reports cumulative incidence of treatments, outcomes and adverse events calculated by Kaplan–Meier survival methods. Results A total of 166 patients, enrolled a median of 6 weeks after JIA diagnosis at 10 centres, were included. The median age at diagnosis was 9 years [interquartile range (IQR) 3, 13], 61% were female and 51% had oligoarticular JIA. The median three-variable clinical Juvenile Arthritis Disease Activity Score was 6.5 (IQR 4, 10) at enrolment, and the median time to first attainment of clinically inactive disease (CID) was 24 weeks (by 1 year, 81%). Within 1 year of diagnosis, 70% of patients had started a DMARD and 35% a biologic agent. The rates of adverse events and serious adverse events were 60 and 5.8 per 100 patient-years, respectively. Conclusion This streamlined and flexible registry minimizes the burden of data collection and interference with clinic operations. Initial findings suggest that treatments for newly diagnosed patients with JIA in Canada have intensified, and now 81% of patients attain CID within 1 year of diagnosis. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

64. Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis

Author

Brunner, Hermine I., Ruperto, Nicola, Martini, Alberto, Ramanan, Athimalaipet V., Cuttica, Ruben J., Weiss, Jennifer E., Henrickson, Michael, Schmeling, Heinrike, Anton, Jordi, Minden, Kirsten, Horneff, Gerd, Luz Gamir-Gamir, Maria, Hufnagel, Markus, Douglass, Wendy, Wells, Chris, Wimalasundera, Sunethra, Mallalieu, Navita L., Lovell, Daniel J., De Benedetti, Fabrizio, Brunner, Hermine I., Ruperto, Nicola, Martini, Alberto, Ramanan, Athimalaipet V., Cuttica, Ruben J., Weiss, Jennifer E., Henrickson, Michael, Schmeling, Heinrike, Anton, Jordi, Minden, Kirsten, Horneff, Gerd, Luz Gamir-Gamir, Maria, Hufnagel, Markus, Douglass, Wendy, Wells, Chris, Wimalasundera, Sunethra, Mallalieu, Navita L., Lovell, Daniel J., and De Benedetti, Fabrizio

Published
2018

65. Additional file 1: of Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Author

Guzman, Jaime, Kerr, Tristan, Ward, Leanne, Jinhui Ma, Kiem Oen, Rosenberg, Alan, Feldman, Brian, Boire, Gilles, Houghton, Kristin, Dancey, Paul, Scuccimarri, Rosie, Bruns, Alessandra, Huber, Adam, Duffy, Karen Watanabe, Shiff, Natalie, Berard, Roberta, Levy, Deborah, Stringer, Elizabeth, Morishita, Kimberly, Johnson, Nicole, Cabral, David, LarchĂŠ, Maggie, Petty, Ross, Laxer, Ronald, Silverman, Earl, Paivi Miettunen, Anne-Laure Chetaille, Haddad, Elie, Spiegel, Lynn, Turvey, Stuart, Schmeling, Heinrike, Lang, Bianca, Ellsworth, Janet, Ramsey, Suzanne, Roth, Johannes, Campillo, Sarah, Benseler, Susanne, GaĂŤlle ChĂŠdeville, Rayfel Schneider, Tse, Shirley, Bolaria, Roxana, Gross, Katherine, Feldman, Debbie, Cameron, Bonnie, Jurencak, Roman, Dorval, Jean, LeBlanc, Claire, Cyr, Claire St., Gibbon, Michele, Yeung, Rae, CiarĂĄn Duffy, and Tucker, Lori

Abstract

Growth and Weight Gain in Juvenile Arthritis. (DOCX 2958 kb)

Published
2017
Full Text
View/download PDF

66. 06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis

Author

Jafri, Shazad, primary, Ramanan, Athimalaipet V., additional, De Benedetti, Fabrizio, additional, Ruperto, Nicolino, additional, Lovell, Daniel, additional, Cuttica, Ruben, additional, Weiss, Jennifer E., additional, Henrickson, Michael, additional, Schmeling, Heinrike, additional, Anton, Jordi, additional, Minden, Kirsten, additional, Hsu, Joy, additional, Bharucha, Kamal, additional, Wimalasundera, Sunethra, additional, Kadva, Alysha K., additional, Upmanyu, Ruchi, additional, Mallalieu, Navita L., additional, Martini, Alberto, additional, and Brunner, Hermine, additional

Published
2017
Full Text
View/download PDF

67. Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort

Author

Shiff, Natalie J., primary, Tupper, Susan, additional, Oen, Kiem, additional, Guzman, Jaime, additional, Lim, Hyun, additional, Lee, Chel Hee, additional, Bryce, Rhonda, additional, Huber, Adam M., additional, Boire, Gilles, additional, Dancey, Paul, additional, Feldman, Brian, additional, Laxer, Ronald, additional, Miettunen, Paivi, additional, Schmeling, Heinrike, additional, Watanabe Duffy, Karen, additional, Levy, Deborah M., additional, Turvey, Stuart, additional, Bolaria, Roxana, additional, Bruns, Alessandra, additional, Cabral, David A., additional, Campillo, Sarah, additional, Chédeville, Gaëlle, additional, Feldman, Debbie Ehrmann, additional, Haddad, Elie, additional, Houghton, Kristin, additional, Johnson, Nicole, additional, Jurencak, Roman, additional, Lang, Bianca, additional, Larche, Maggie, additional, Morishita, Kimberly, additional, Ramsey, Suzanne, additional, Roth, Johannes, additional, Schneider, Rayfel, additional, Scuccimarri, Rosie, additional, Spiegel, Lynn, additional, Stringer, Elizabeth, additional, Tse, Shirley M., additional, Yeung, Rae, additional, Duffy, Ciarán M., additional, and Tucker, Lori B., additional

Published
2017
Full Text
View/download PDF

68. Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Author

Guzman, Jaime, primary, Kerr, Tristan, additional, Ward, Leanne M., additional, Ma, Jinhui, additional, Oen, Kiem, additional, Rosenberg, Alan M., additional, Feldman, Brian M., additional, Boire, Gilles, additional, Houghton, Kristin, additional, Dancey, Paul, additional, Scuccimarri, Rosie, additional, Bruns, Alessandra, additional, Huber, Adam M., additional, Watanabe Duffy, Karen, additional, Shiff, Natalie J., additional, Berard, Roberta A., additional, Levy, Deborah M., additional, Stringer, Elizabeth, additional, Morishita, Kimberly, additional, Johnson, Nicole, additional, Cabral, David A., additional, Larché, Maggie, additional, Petty, Ross E., additional, Laxer, Ronald M., additional, Silverman, Earl, additional, Miettunen, Paivi, additional, Chetaille, Anne-Laure, additional, Haddad, Elie, additional, Spiegel, Lynn, additional, Turvey, Stuart E., additional, Schmeling, Heinrike, additional, Lang, Bianca, additional, Ellsworth, Janet, additional, Ramsey, Suzanne E., additional, Roth, Johannes, additional, Campillo, Sarah, additional, Benseler, Susanne, additional, Chédeville, Gaëlle, additional, Schneider, Rayfel, additional, Tse, Shirley M. L., additional, Bolaria, Roxana, additional, Gross, Katherine, additional, Feldman, Debbie, additional, Cameron, Bonnie, additional, Jurencak, Roman, additional, Dorval, Jean, additional, LeBlanc, Claire, additional, St. Cyr, Claire, additional, Gibbon, Michele, additional, Yeung, Rae S. M., additional, Duffy, Ciarán M., additional, and Tucker, Lori B., additional

Published
2017
Full Text
View/download PDF

69. Real‐World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort

Author

Chhabra, Amieleena, Oen, Kiem, Huber, Adam M., Shiff, Natalie J., Boire, Gilles, Benseler, Susanne M., Berard, Roberta A., Scuccimarri, Rosie, Feldman, Brian M., Lim, Lily Siok Hoon, Barsalou, Julie, Bruns, Alessandra, Cabral, David A., Chédeville, Gaëlle, Ellsworth, Janet, Houghton, Kristin, Lang, Bianca, Morishita, Kimberly, Rumsey, Dax G., Rosenberg, Alan M., Tse, Shirley M., Watanabe Duffy, Karen, Duffy, Ciaran M., Guzman, Jaime, Bolaria, Roxana, Gross, Katherine, Turvey, Stuart E., Chan, Mercedes, Tucker, Lori B., Petty, Ross, Johnson, Nicole, Luca, Nadia, Miettunen, Paivi, Schmeling, Heinrike, Gerhold, Kerstin, Larché, Maggie, Levy, Deborah M., Laxer, Ronald M., Feldman, Debbie, Spiegel, Lynn, Schneider, Rayfel, Silverman, Earl, Cameron, Bonnie, Yeung, Rae S. M., Roth, Johannes, Jurencak, Roman, Gibbon, Michele, Chetaille, Anne‐Laure, Dorval, Jean, Campillo, Sarah, LeBlanc, Claire, Chédeville, Gaëlle, Haddad, Elie, Cyr, Claire St., Ramsey, Suzanne E., Stringer, Elizabeth, and Dancey, Paul

Abstract

Undervaluing the effectiveness of conventional treatments may lead to overtreatment with biologic medications in children with juvenile idiopathic arthritis (JIA). Using data from a nationwide inception cohort and strict methods to control bias, the aim of our study was to estimate the real‐world effectiveness of simple JIAtreatment strategies recommended in current guidelines. Children with JIAwho were recruited at 16 Canadian centers from 2005 to 2010 were followed for up to 5 years. For each child, all observed treatment changes over time were assessed by independent physicians using prospectively collected data and published response criteria. Success was defined as attainment of inactive disease or maintenance of this state when stepping down treatment; minimally active disease was deemed acceptable for children with polyarticular JIA. Success rates were calculated for treatments tried ≥25 times, and logistic regression analysis identified features associated with success. A total of 4,429 treatment episodes were observed in 1,352 children. Nonsteroidal antiinflammatory drug (NSAID) monotherapy was attempted 697 times, mostly as initial treatment when <5 joints were involved, with a 54.4% success rate (95% confidence interval [95% CI] 50.3–58.6). NSAIDs plus joint injections had a 64.7% success rate (95% CI59.8–69.7). Adding methotrexate to NSAIDs and/or joint injections (attempted 566 times) had a 60.5% success rate (95% CI55.7–65.3). In adjusted analyses, each additional active joint reduced chances of success for treatment with NSAIDs (odds ratio [OR] 0.90 [95% CI0.85–0.94]) and for methotrexate combinations (OR0.96 [95% CI0.94–0.99]). Each additional year after disease onset reduced chances of success for treatment with methotrexate combinations (OR0.83 [95% CI0.72–0.95]). These real‐world effectiveness estimates show that conventional nonbiologic treatment strategies that are recommended in current guidelines are effective in achieving treatment targets in many children with JIA.

Published
2020
Full Text
View/download PDF

70. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis : An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative

Author

Rider, Lisa G., Aggarwal, Rohit, Pistorio, Angela, Bayat, Nastaran, Erman, Brian, Feldman, Brian M., Huber, Adam M., Cimaz, Rolando, Cuttica, Rubén J., de Oliveira, Sheila Knupp, Lindsley, Carol B., Pilkington, Clarissa A., Punaro, Marilynn, Ravelli, Angelo, Reed, Ann M., Rouster-Stevens, Kelly, van Royen-Kerkhof, Annet, Dressler, Frank, Magalhaes, Claudia Saad, Constantin, Tamás, Davidson, Joyce E., Magnusson, Bo, Russo, Ricardo, Villa, Luca, Rinaldi, Mariangela, Rockette, Howard, Lachenbruch, Peter A., Miller, Frederick W., Vencovsky, Jiri, Ruperto, Nicolino, Hansen, Paul, Apaz, Maria, Bowyer, Suzanne, Curran, Megan, Davidson, Joyce, Griffin, Thomas, Huber, Adam H., Jones, Olcay, Kim, Susan, Lang, Bianca, Lindsley, Carol, Lovell, Daniel, Saad Magalhaes, Claudia, Pachman, Lauren M., Pilkington, Clarissa, Ponyi, Andrea, Quartier, Pierre, Ramanan, Athimalaipet V., Reed, Ann, Rennebohm, Robert, Sherry, David D., Silva, Clovis A., Stringer, Elizabeth, Wallace, Carol, Oddis, Chester V., Avcin, Tadej, Becker, Mara, Beresford, Michael W., Cuttica, Ruben, Dvergsten, Jeffrey, Feitosa de Oliveira, Sheila Knupp, Leme Ferriani, Virginia Paes, Flato, Berit, Gerloni, Valeria, Henrickson, Michael, Hinze, Claas, Hoeltzel, Mark, Ibarra, Maria, Ilowite, Norman, Imundo, Lisa, Kingsbury, Daniel, Martini, Alberto, Maguiness, Sheilagh, Maillard, Susan, Mathiesen, Pernille, Mccann, Liza, Nielsen, Susan, Passo, Murray, Rabinovich, Egla, Rivas-Chacon, Rafael, Byun Robinson, Angela, Rutkowska-Sak, Lidia, Sallum, Adriana, Sanner, Helga, Schmeling, Heinrike, Selcen, Duygu, Shaham, Bracha, Spencer, Charles H., Sundel, Robert, Tardieu, Marc, Thatayatikom, Akaluck, van der Net, Janjaap, Wahezi, Dawn, Zulian, Francesco, Analysis, Conjoint, Knupp Feitosa de Oliveira, Sheila, Cuttica, Rubén, Amato, Anthony, Chinoy, Hector, Cooper, Robert G., Dastmalchi, Maryam, de Visser, Marianne, Fiorentino, David, Isenberg, David, Katz, James, Mammen, Andrew, Ytterberg, Steven R., NIH, Univ Pittsburgh, Ist Giannina Gaslini, Social & Sci Syst Inc, Hosp Sick Children, IWK Hlth Ctr, Univ Florence, Univ Buenos Aires, Universidade Federal do Rio de Janeiro (UFRJ), Univ Kansas, Great Ormond St Hosp Sick Children, Univ Texas Dallas, Univ Genoa, Duke Univ, Emory Univ, Univ Med Ctr Utrecht, Hannover Med Sch, Universidade Estadual Paulista (Unesp), Semmelweis Univ, Royal Hosp Sick Children, Karolinska Univ Hosp, Hosp Pediatria Garrahan, Charles Univ Prague, and Neurology

Subjects
Genetics and Molecular Biology (all), Logistic regression, Severity of Illness Index, Biochemistry, 0302 clinical medicine, Fructose-Bisphosphate Aldolase, Surveys and Questionnaires, Outcome Assessment, Health Care, Immunology and Allergy, 030212 general & internal medicine, Child, Creatine Kinase, Societies, Medical, Juvenile dermatomyositis, Randomized Controlled Trials as Topic, Alanine Transaminase, Orvostudományok, Adult dermatomyositis, Conjoint analysis, Europe, Treatment Outcome, Child, Preschool, Antirheumatic Agents, Cyclosporine, Adolescent, Aspartate Aminotransferases, Dermatomyositis, Glucocorticoids, Humans, L-Lactate Dehydrogenase, Logistic Models, Methotrexate, Muscle Strength, Outcome Assessment (Health Care), Patient Reported Outcome Measures, Prednisone, Reproducibility of Results, Rheumatology, Rituximab, United States, Immunology, Adult, medicine.medical_specialty, Potentially all pairwise rankings of all possible alternatives, Consensus, Polymyositis, Klinikai orvostudományok, Sensitivity and Specificity, Article, General Biochemistry, Genetics and Molecular Biology, Autoimmune Diseases, 03 medical and health sciences, Rheumatic Diseases, Medical, Severity of illness, medicine, Preschool, 030203 arthritis & rheumatology, Myositis, Biochemistry, Genetics and Molecular Biology(all), business.industry, Gold standard, medicine.disease, Treatment, Clinical trial, Biochemistry, Genetics and Molecular Biology (all), Physical therapy, Societies, business, Rheumatism, 030217 neurology & neurosurgery, Genetics and Molecular Biology(all)
Abstract

Made available in DSpace on 2018-11-28T06:57:31Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-05-01 Intramural NIH HHS To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (>= 30), moderate (>= 45), and major (>= 70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p= 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p< 0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement. NIH, NIEHS, Bethesda, MD USA Univ Pittsburgh, Pittsburgh, PA 15260 USA Ist Giannina Gaslini, Genoa, Italy Social & Sci Syst Inc, Durham, NC USA Hosp Sick Children, Toronto, ON, Canada IWK Hlth Ctr, Halifax, NS, Canada Univ Florence, Florence, Italy Univ Buenos Aires, Hosp Ninos Pedro Elizalde, Buenos Aires, DF, Argentina Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil Univ Kansas, Med Ctr, Kansas City, KS 66103 USA Great Ormond St Hosp Sick Children, Children NHS Trust, London, England Univ Texas Dallas, Southwester Med Ctr, Dallas, TX 75083 USA Univ Genoa, Ist Giannina Gaslini, Pediatria Reumatol 2, Genoa, Italy Duke Univ, Durham, NC 27706 USA Emory Univ, Sch Med, Atlanta, GA 30322 USA Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Utrecht, Netherlands Hannover Med Sch, Hannover, Germany Univ Estadual Paulista, Sao Paulo, Brazil Semmelweis Univ, Budapest, Hungary Royal Hosp Sick Children, Glasgow, Lanark, Scotland Royal Hosp Sick Children, Edinburgh, Midlothian, Scotland Karolinska Univ Hosp, Stockholm, Sweden Hosp Pediatria Garrahan, Buenos Aires, DF, Argentina Ist Giannina Gaslini, PRINTO, Pediatria Reumatol 2, Genoa, Italy Charles Univ Prague, Prague, Czech Republic Univ Estadual Paulista, Sao Paulo, Brazil Intramural NIH HHS: ZIA ES101081-13 Intramural NIH HHS: ZIA ES101081-14 Intramural NIH HHS: Z99 ES999999 Intramural NIH HHS: ZIA ES101081-15 Intramural NIH HHS: ZIA ES101081-12

Published
2017
Full Text
View/download PDF

71. Die Wirksamkeit und Sicherheit von Methotrexat bei anhaltend oligoartikulärer juveniler idiopathischer Arthritis

Author

Schmeling, Heinrike and Horneff, Gerd

Subjects
ddc: 610, Juvenile idiopathische Arthritis, JADAS, 610 Medical sciences, Medicine, Methotrexat
Abstract

Einleitung: Auf der Basis der ACR 2011 Empfehlungen für die Behandlung der anhaltend oligoartikulären JIA ist Methotrexat (MTX) für Kinder mit hoher Krankheitsaktivität und Merkmalen schlechter Prognose nach intraartikulären Glukokortikoiden empfohlen. Bislang steht hierfür[for full text, please go to the a.m. URL], 42. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 28. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 24. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2014
Full Text
View/download PDF

72. Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association

Author

CELLUCCI, TANIA, primary, GUZMAN, JAIME, additional, PETTY, ROSS E., additional, BATTHISH, MICHELLE, additional, BENSELER, SUSANNE M., additional, ELLSWORTH, JANET E., additional, HOUGHTON, KRISTIN M., additional, LeBLANC, CLAIRE M.A., additional, HUBER, ADAM M., additional, LUCA, NADIA, additional, SCHMELING, HEINRIKE, additional, SHIFF, NATALIE J., additional, SOON, GORDON S., additional, and TSE, SHIRLEY M.L., additional

Published
2016
Full Text
View/download PDF

73. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

Author

Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Peng, Lu, Cuttica, Ruben, Keltsev, Vladimir, Xavier, Ricardo M., Calvo, Inmaculada, Nikishina, Irina, Rubio-Pérez, Nadina, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A., Silverman, Earl, Spindler, Alberto, Baildam, Eileen, Gámir, M. Luz, Martin, Alan, Rietschel, Christoph, Siri, Daniel, Smolewska, Elzbieta, Lovell, Daniel, Martini, Alberto, De Benedetti, Fabrizio, Sherrard, T., Johnson, A., Merritt, A., Long, W., Angioloni, Simona, Carenini, Laura, Pallotti, Chiara, Mosci, Eugenia, Garrone, Marco, Gregorini, Irene, Scala, Silvia, Villa, Luca, Silvestri, Giuseppe, Espada, Graciela, Allen, Roger, Chaitow, Jeffrey, Joos, Rik, Wouters, Carine, Knupp, Sheila, Sztajnbok, Flavio, Cabral, David, Houghton, Kristin, Roth, Johannes, Schmeling, Heinrike, Job-Deslandre, Chantal, Jorgensen, Christian, Konepaut, Isabelle, Minden, Kirsten, Weller, Frank, Gerloni, Valeria, Zulian, Francesco, Burgos-Vargas, Ruben, Salazar, Carolina Duarte, Vallejo, Eunice Solis, Calvo, Armando, Chavez, José, Zavaler, Manuel Ferrandiz, Gruenpeter, Anna, Kobusinska, Katarzyna, Sarychev, Alexey, Zholobova, Elena, Ramanan, Athimalaipet, Woo, Patricia, Gedalia, Abraham, Goodman, Steven, Kimura, Yukiko, Onel, Karen, Schikler, Kenneth, and Wouters, Carine

Subjects
Genetics and Molecular Biology (all), Male, DMARDs (biologic), Juvenile Idiopathic Arthritis, Treatment, Adolescent, Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Bronchitis, Cellulitis, Child, Child, Preschool, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Maintenance Chemotherapy, Methotrexate, Pneumonia, Receptors, Interleukin-6, Remission Induction, Treatment Outcome, Rheumatology, Immunology and Allergy, Immunology, Biochemistry, Genetics and Molecular Biology (all), Arthritis, Juvenile, Biochemistry, chemistry.chemical_compound, Monoclonal, Receptors, Medicine, skin and connective tissue diseases, Humanized, Artrite, Connective tissue disease, Rheumatoid arthritis, Combination, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, General Biochemistry, Genetics and Molecular Biology, Antibodies, Tocilizumab, Drug Therapy, Internal medicine, Preschool, Imunossupressores, business.industry, Interleukin-6, Clinical and Epidemiological Research, medicine.disease, Surgery, Método duplo-cego, chemistry, business
Abstract

ObjectiveTo evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).MethodsThis three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) ResultsIn part 1, 188 patients received tocilizumab (ConclusionsTocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis.Trial registration number:NCT00988221.

Published
2014

74. Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.

Author

Bharucha, Kamal N., Brunner, Hermine I., Calvo Penadés, Inmaculada, Nikishina, Irina, Rubio-Pérez, Nadina, Oliveira, Sheila, Kobusinska, Katarzyna, Schmeling, Heinrike, Sztajnbok, Flavio, Weller-Heinemann, Frank, Zholobova, Elena, Zulian, Francesco, Allen, Roger, Chaitow, Jeffrey, Frane, James, Wells, Chris, Ruperto, Nicolino, De Benedetti, Fabrizio, and Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group

Published
2018
Full Text
View/download PDF

75. Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category

Author

Rumsey, Dax G., Guzman, Jaime, Rosenberg, Alan M., Huber, Adam M., Scuccimarri, Rosie, Shiff, Natalie J., Bruns, Alessandra, Feldman, Brian M., Eurich, Dean T., Benseler, Susanne, Berard, Roberta, Boire, Gilles, Bolaria, Roxana, Cabral, David, Cameron, Bonnie, Campillo, Sarah, Chan, Mercedes, Chédeville, Gaëlle, Chetaille, Anne‐Laure, Dancey, Paul, Dorval, Jean, Duffy, Ciarán, Ellsworth, Janet, Feldman, Debbie, Gross, Katherine, Haddad, Ellie, Houghton, Kristin, Johnson, Nicole, Jurencak, Roman, Lang, Bianca, Larché, Maggie, Laxer, Ronald, LeBlanc, Claire, Levy, Deborah, Luca, Nadia, Miettunen, Paivi, Morishita, Kimberly, Oen, Kiem, Petty, Ross, Ramsey, Suzanne, Roth, Johannes, Saint‐Cyr, Claire, Schmeling, Heinrike, Schneider, Rayfel, Silverman, Earl, Spiegel, Lynn, Stringer, Elizabeth, Tse, Shirley, Tucker, Lori, Turvey, Stuart, Watanabe Duffy, Karen, and Yeung, Rae

Abstract

To estimate the impact of enthesitis on patient‐reported outcomes in children with juvenile idiopathic arthritis (JIA), irrespective of JIAcategory. Children enrolled in the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort were studied. Entheseal tenderness by physician examination in 33 defined locations, Juvenile Arthritis Quality of Life Questionnaire (JAQQ), Quality of My Life (QoML) Questionnaire, Childhood Health Assessment Questionnaire (C‐HAQ), and a pain visual analog scale were completed at enrollment, every 6 months for 2 years, and then yearly up to 5 years. Analyses consisted of descriptive statistics, linear mixed models for longitudinal data, and analysis of covariance. Among 1,371 patients followed for a median of 35.3 months (interquartile range 22.1, 49.2), 214 (16%) had enthesitis, of whom 137 (64%) were classified as having enthesitis‐related arthritis. After adjusting for JIAcategory and covariates, children with enthesitis reported higher JAQQ(mean raw score 2.71 versus 2.16, adjusted difference 0.41 points; 95% confidence interval [95% CI] 0.22, 0.59), higher C‐HAQ(0.47 versus 0.31, adjusted difference 0.14 points; 95% CI0.07, 0.22), higher pain (3.01 versus 1.68, adjusted difference 0.94 points; 95% CI0.64, 1.25), and lower QoML(7.02 versus 8.23, adjusted difference –0.80 points; 95% CI–1.09, –0.51) scores than children without enthesitis. These differences persisted up to 5 years. Children with enthesitis, regardless of JIAcategory, report worse patient‐reported outcomes than those without enthesitis. Thus, enthesitis should be assessed in all children with JIA.

Published
2020
Full Text
View/download PDF

76. Consensus Treatments for Moderate Juvenile Dermatomyositis: Beyond the First Two Months: Results of the Second Children’s Arthritis and Rheumatology Research Alliance Consensus Conference

Author

Huber, Adam M., Robinson, Angela B., Reed, Ann M., Abramson, Leslie, Bout-Tabaku, Sharon, Carrasco, Ruy, Curran, Megan, Feldman, Brian M., Gewanter, Harry, Griffin, Thomas, Haines, Kathleen, Sanzari, Joseph M., Hoeltzel, Mark F., Isgro, Josephine, Kahn, Philip, Lang, Bianca, Lawler, Patti, Shaham, Bracha, Schmeling, Heinrike, Scuccimarri, Rosie, Shishov, Michael, Stringer, Elizabeth, Wohrley, Julie, Ilowite, Norman T., and Wallace, Carol

Subjects
medicine.medical_specialty, Pediatrics, Weakness, Time Factors, Adolescent, Childhood arthritis, Alternative medicine, Article, Dermatomyositis, law.invention, Rheumatology, Randomized controlled trial, law, Internal medicine, medicine, Humans, Child, Juvenile dermatomyositis, Response rate (survey), Evidence-Based Medicine, Dose-Response Relationship, Drug, business.industry, medicine.disease, Clinical trial, Treatment Outcome, Child, Preschool, Practice Guidelines as Topic, Physical therapy, Steroids, medicine.symptom, business
Abstract

Juvenile dermatomyositis (JDM) is a rare, autoimmune illness characterized by muscle and skin involvement, with less frequent involvement of other systems, including the gastrointestinal tract and lungs. Although previously associated with significant mortality (1), morbidity is a much greater problem since the introduction of corticosteroids as a mainstay of therapy. Many children experience complications of their underlying disease such as contractures, weakness, disfiguring skin lesions and painful calcinosis. They may also develop complications secondary to prolonged courses of treatment, in particular those side effects related to chronic corticosteroid use(2). There is very little data on which to base treatment decisions in JDM. Even the most commonly used therapies, corticosteroids and/or methotrexate, have not been studied in clinical trials. In fact, at the time of this writing, no randomized clinical trials of therapy in JDM have been published. This lack of data has resulted in wide variation in treatment of children with JDM. This has been documented by Stringer et al. who reported the results of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey (3). Using a series of representative clinical scenarios of children with JDM, members of CARRA were surveyed with regard to investigations and therapies. The survey was answered by 141 CARRA members (84% response rate), and revealed a remarkable degree of variation in dose, duration and route of corticosteroids, and use of methotrexate and other immunosuppressive agents (3). In 2007, 12 pediatric rheumatologists experienced in the care of children with JDM participated in a CARRA-initiated consensus conference in Toronto, Ontario, Canada (4). This meeting had the explicit goal of defining a small number of consensus treatment plans for the initial treatment (up to 2 months) of children with moderate JDM. Using data from the CARRA JDM treatment survey (3) and expert opinion, the meeting participants were able to develop 3 consensus treatment plans. It is important to note that these treatment plans were not intended to be innovative. Rather, the goal was to develop treatment plans which were similar to approaches that were being used commonly in the pediatric rheumatology community. It was hoped that by developing consensus treatment plans, variation in treatment approaches could be decreased and data could be prospectively collected. This would allow for comparative research and would be the first step in defining evidence-based treatments for moderate JDM. After the success of the Toronto consensus meeting, it was recognized that for these treatment plans to be studied, they needed to be extended beyond 2 months of treatment. The goal of the present effort was to use consensus methods, and the considerable expertise contained within the CARRA organization, to extend the 3 previously developed treatment plans to span the full course of treatment of children with moderate JDM.

Published
2012

77. Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls

Author

Schmeling, Heinrike, primary, Mahler, Michael, additional, Levy, Deborah M., additional, Moore, Katharine, additional, Stevens, Anne M., additional, Wick, James, additional, McMillan, Jacob D., additional, Horneff, Gerd, additional, Assassi, Shervin, additional, Charles, Julio, additional, Salazar, Gloria, additional, Mayes, Maureen D., additional, Silverman, Earl D., additional, Klien-Gitelman, Marissa, additional, Lee, Tzelan, additional, Brunner, Hermine I., additional, Reed, Ann M., additional, and Fritzler, Marvin J., additional

Published
2015
Full Text
View/download PDF

78. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Author

Guzman, Jaime, primary, Oen, Kiem, additional, Huber, Adam M, additional, Watanabe Duffy, Karen, additional, Boire, Gilles, additional, Shiff, Natalie, additional, Berard, Roberta A, additional, Levy, Deborah M, additional, Stringer, Elizabeth, additional, Scuccimarri, Rosie, additional, Morishita, Kimberly, additional, Johnson, Nicole, additional, Cabral, David A, additional, Rosenberg, Alan M, additional, Larché, Maggie, additional, Dancey, Paul, additional, Petty, Ross E, additional, Laxer, Ronald M, additional, Silverman, Earl, additional, Miettunen, Paivi, additional, Chetaille, Anne-Laure, additional, Haddad, Elie, additional, Houghton, Kristin, additional, Spiegel, Lynn, additional, Turvey, Stuart E, additional, Schmeling, Heinrike, additional, Lang, Bianca, additional, Ellsworth, Janet, additional, Ramsey, Suzanne E, additional, Bruns, Alessandra, additional, Roth, Johannes, additional, Campillo, Sarah, additional, Benseler, Susanne, additional, Chédeville, Gaëlle, additional, Schneider, Rayfel, additional, Tse, Shirley M L, additional, Bolaria, Roxana, additional, Gross, Katherine, additional, Feldman, Brian, additional, Feldman, Debbie, additional, Cameron, Bonnie, additional, Jurencak, Roman, additional, Dorval, Jean, additional, LeBlanc, Claire, additional, St. Cyr, Claire, additional, Gibbon, Michele, additional, Yeung, Rae S M, additional, Duffy, Ciarán M, additional, and Tucker, Lori B, additional

Published
2015
Full Text
View/download PDF

79. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

Author

Guzman, Jaime, primary, Oen, Kiem, additional, Tucker, Lori B, additional, Huber, Adam M, additional, Shiff, Natalie, additional, Boire, Gilles, additional, Scuccimarri, Rosie, additional, Berard, Roberta, additional, Tse, Shirley M L, additional, Morishita, Kimberly, additional, Stringer, Elizabeth, additional, Johnson, Nicole, additional, Levy, Deborah M, additional, Duffy, Karen Watanabe, additional, Cabral, David A, additional, Rosenberg, Alan M, additional, Larché, Maggie, additional, Dancey, Paul, additional, Petty, Ross E, additional, Laxer, Ronald M, additional, Silverman, Earl, additional, Miettunen, Paivi, additional, Chetaille, Anne-Laure, additional, Haddad, Elie, additional, Houghton, Kristin, additional, Spiegel, Lynn, additional, Turvey, Stuart E, additional, Schmeling, Heinrike, additional, Lang, Bianca, additional, Ellsworth, Janet, additional, Ramsey, Suzanne, additional, Bruns, Alessandra, additional, Campillo, Sarah, additional, Benseler, Susanne, additional, Chédeville, Gaëlle, additional, Schneider, Rayfel, additional, Yeung, Rae, additional, and Duffy, Ciarán M, additional

Published
2014
Full Text
View/download PDF

82. A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH

Author

Ravelli, Angelo, primary, Ruperto, Nicolino, additional, Pederzoli, Silvia, additional, Burgos-Vargas, Ruben, additional, Kobusinska, Katarzyna, additional, Schmeling, Heinrike, additional, Sztajnbok, Flavio, additional, Weller-Heinemann, Frank, additional, Zholobova, Elena, additional, Zulian, Francesco, additional, Allen, Roger, additional, Chaitow, Jeffrey, additional, Keane, Caroline, additional, Wells, Chris, additional, Martini, Alberto, additional, Lovell, Daniel J., additional, and De Benedetti, Fabrizio, additional

Published
2014
Full Text
View/download PDF

83. Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis

Author

LEBLANC, CLAIRE M.A., primary, LANG, BIANCA, additional, BENCIVENGA, ALMA, additional, CHETAILLE, ANNE-LAURE, additional, DANCEY, PAUL, additional, DENT, PETER, additional, MIETTUNEN, PAIVI, additional, OEN, KIEM, additional, ROSENBERG, ALAN, additional, ROTH, JOHANNES, additional, SCUCCIMARRI, ROSIE, additional, TSE, SHIRLEY M.L., additional, BENSELER, SUSANNE, additional, CABRAL, DAVID A., additional, CAMPILLO, SARAH, additional, CHÉDEVILLE, GAËLLE, additional, DUFFY, CIARAN M., additional, DUFFY, KAREN WATANABE, additional, HADDAD, ELIE, additional, HUBER, ADAM M., additional, LAXER, RONALD, additional, LEVY, DEBORAH, additional, JOHNSON, NICOLE, additional, RAMSEY, SUZANNE, additional, SHIFF, NATALIE, additional, SCHMELING, HEINRIKE, additional, SCHNEIDER, RAYFEL, additional, STRINGER, ELIZABETH, additional, YEUNG, RAE S.M., additional, and TUCKER, LORI B., additional

Published
2012
Full Text
View/download PDF

84. Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada.

Author

Barber, Claire E. H., Marshall, Deborah A., Mosher, Dianne P., Akhavan, Pooneh, Tucker, Lori, Houghton, Kristin, Batthish, Michelle, Levy, Deborah M., Schmeling, Heinrike, Ellsworth, Janet, Tibollo, Heidi, Grant, Sean, Khodyakov, Dmitry, Lacaille, Diane, and Arthritis Alliance of Canada Performance Measurement Development Panel

Published
2016
Full Text
View/download PDF

88. Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two: Genoa, Italy. 28 September – 01 October 2016

Author

Lomakina, Olga, Alekseeva, Ekaterina, Valieva, Sania, Bzarova, Tatiana, Nikishina, Irina, Zholobova, Elena, Rodionovskaya, Svetlana, Kaleda, Maria, Nakagishi, Yasuo, Shimizu, Masaki, Mizuta, Mao, Yachie, Akihiro, Sugita, Yuko, Okamoto, Nami, Shabana, Kousuke, Murata, Takuji, Tamai, Hiroshi, Smith, Eve M., Yin, Peng, Jorgensen, Andrea L., Beresford, Michael W., Eleuteri, Antonio, Goilav, Beatrice, Lewandowski, Laura, Phuti, Angel, Wahezi, Dawn, Rubinstein, Tamar, Jones, Caroline, Newland, Paul, Marks, Stephen, Corkhill, Rachel, Ekdawy, Diana, Pilkington, Clarissa, Tullus, Kjell, Putterman, Chaim, Scott, Chris, Fisher, Antony C., Jorgensen, Andrea, Batu, Ezgi Deniz, Kosukcu, Can, Taskiran, Ekim, Akman, Sema, Ozturk, Kubra, Sozeri, Betul, Unsal, Erbil, Ekinci, Zelal, Bilginer, Yelda, Alikasifoglu, Mehmet, Ozen, Seza, Lythgoe, Hanna, Brunner, Hermine I., Gulati, Gaurav, Jones, Jordan T., Altaye, Mekibib, Eaton, Jamie, Difrancesco, Mark, Yeo, Joo Guan, Leong, Jingyao, Bathi, Loshinidevi D/O Thana, Arkachaisri, Thaschawee, Albani, Salvatore, Abdelrahman, Nagla, Beresford, Michael W, Leone, Valentina, Groot, Noortje, Shaikhani, D., Bultink, I. E. M., Bijl, M., Dolhain, R. J. E. M., Teng, Y. K. O., Zirkzee, E., de Leeuw, K., Fritsch-Stork, R., Kamphuis, S. S. M., Wright, Rachael D., Abdawani, Reem, Al Shaqshi, Laila, Al Zakwani, Ibrahim, Gormezano, Natali W., Kern, David, Pereira, Oriany L., Esteves, Gladys C. C., Sallum, Adriana M., Aikawa, Nadia E., Pereira, Rosa M., Silva, Clovis A., Bonfa, Eloisa, Beckmann, Jessica, Bartholomä, Nora, Venhoff, Nils, Henneke, Philipp, Salzer, Ulrich, Janda, Ales, Boteanu, Alina Lucica, Corral, Sandra Garrote, Giraldo, Alberto Sifuentes, Gámir, Mariluz Gámir, Mendoza, Antonio Zea, Adrovic, Amra, Dedeoglu, Reyhan, Sahin, Sezgin, Barut, Kenan, Koka, Aida, Oztunc, Funda, Kasapcopur, Ozgur, Rodriguez-Lozano, Ana Luisa, Rivas-Larrauri, Francisco, de la Puente, Silvestre García, Alves, Andressa G. F., Giacomin, Maria F. D. A., Farhat, Juliana, Braga, Alfésio L. F., Sallum, Adriana M. E., Campos, Lúcia M. D. A., Pereira, Luiz A. A., Lichtenfels, Ana J. D. F. C., Silva, Clóvis A., Farhat, Sylvia C. L., Acar, Banu, Ozcakar, Z. Birsin, Çakar, Nilgün, Uncu, Nermin, Gür, Gökçe, Özdel, Semanur, Yalçınkaya, Fatoş, Scott, Christiaan, Brice, Nicky, Nourse, Peter, Arango, Christine, Mosquera, Angela C., Malagon, Clara, Sakamoto, Ana P., Silva, Marco F. C. D., Lopes, Ananadreia S., Russo, Gleice C. S., Sallum, Adriana E. M., Kozu, Katia, Bonfá, Eloisa, Saad-Magalhães, Claudia, Pereira, Rosa M. R., Len, Claudio A., Terreri, Maria T., Suri, Deepti, Didel, Siyaram, Rawat, Amit, Singh, Surjit, Maritsi, Despoina, Onoufriou, MArgarita, Vougiouka, Olga, Tsolia, Maria, Bosak, Edi Paleka, Vidović, Mandica, Lamot, Mirta, Lamot, Lovro, Harjaček, Miroslav, Van Nieuwenhove, Erika, Liston, Adrian, Wouters, Carine, Tahghighi, Fatemeh, Ziaee, Vahid, Raeeskarami, Seid-Reza, Aguiar, Francisca, Pereira, Sandra, Rodrigues, Mariana, Moura, Cláudia, Rocha, Gustavo, Guimarães, Hercília, Brito, Iva, Fonseca, Rita, Horneff, Gerd, Klein, Ariane, Minden, Kirsten, Huppertz, Hans-Iko, Weller-Heinemann, Frank, Kuemmerle-Deschner, Jasmin, Haas, J-Peter, Hospach, Anton, Menendez-Castro, Ricardo, Huegle, Boris, Haas, Johannes-Peter, Swart, Joost, Giancane, Gabriella, Bovis, Francesca, Castagnola, Elio, Groll, Andreas, Lovell, Daniel J., Wolfs, Tom, Hofer, Michael, Panaviene, Violeta, Nielsen, Susan, Anton, Jordi, Uettwiller, Florence, Stanevicha, Valda, Trachana, Maria, Marafon, Denise Pires, Ailioaie, Constantin, Tsitsami, Elena, Kamphuis, Sylvia, Herlin, Troels, Doležalová, Pavla, Susic, Gordana, Flatø, Berit, Sztajnbok, Flavio, Pistorio, Angela, Martini, Alberto, Wulffraat, Nico, Ruperto, Nicolino, Gattorno, Marco, Brucato, Antonio, Finetti, Martina, Lazaros, George, Maestroni, Silvia, Carraro, Mara, Cumetti, Davide, Carobbio, Alessandra, Lorini, Monia, Rimini, Alessandro, Marcolongo, Renzo, Valenti, Anna, Erre, Gian Luca, Belli, Riccardo, Gaita, Fiorenzo, Sormani, Maria Pia, Imazio, Massimo, Abinun, Mario, Smith, Nicola, Rapley, Tim, McErlane, Flora, Kearsley-Fleet, Lianne, Hyrich, Kimme L., Foster, Helen, Tzaribachev, Nikolay, Zeft, Andrew, Cimaz, Rolando, Bohnsack, John, Griffin, Thomas, Carrasco, Ruy, Dare, Jason, Foeldvari, Ivan, Vehe, Richard, Simon, Teresa, Brunner, Hermine, Verazza, S., Davì, S., Consolaro, A., Insalaco, A., Gerloni, V., Cimaz, R., Zulian, F., Pastore, S., Corona, F., Conti, G., Barone, P., Cattalini, M., Cortis, E., Breda, L., Olivieri, A. N., Civino, A., Podda, R., Rigante, D., La Torre, F., D’Angelo, G., Jorini, M., Gallizzi, R., Maggio, M. C., Consolini, R., De Fanti, A., Alpigiani, M. G., Martini, A., Ravelli, A., Kısaarslan, Aysenur Pac, Gunduz, Zubeyde, Dusunsel, Ruhan, Dursun, Ismail, Poyrazoglu, Hakan, Kuchinskaya, Ekaterina, Abduragimova, Farida, Kostik, Mikhail, Sundberg, Erik, Omarsdottir, Soley, Klevenvall, Lena, Erlandsson-Harris, Helena, Basbozkurt, Gokalp, Erdemli, Ozge, Simsek, Dogan, Yazici, Fatih, Karsioglu, Yildirim, Tezcaner, Aysen, Keskin, Dilek, Ozkan, Huseyin, Acikel, Cengizhan, Demirkaya, Erkan, Orbán, Ilonka, Sevcic, Krisztina, Brodszky, Valentin, Kiss, Emese, Tekko, Ismaiel A., Rooney, Madeleine, McElnay, James, Taggart, Cliff, McCarthy, Helen, Donnelly, Ryan F., Slatter, Mary, Nademi, Zohreh, Friswell, Mark, Jandial, Sharmila, Flood, Terence, Hambleton, Sophie, Gennery, Andrew, Cant, Andrew, Duong, Phoi-Ngoc, Koné-Paut, Isabelle, Filocamo, Giovanni, Gamir, María Luz, Sanner, Helga, Carenini, Laura, Topdemir, Mesut, Karslioglu, Yildirim, Gok, Faysal, Tsurikova, Nadezhda, Ligostaeva, Elena, Ramchurn, Navdha R., Kostareva, O., Nikishina, I., Arsenyeva, S., Rodionovskaya, S., Kaleda, M., Alexeev, D., Dursun, Ismail Dursun, Murias, Sara, Barral, Estefania, Alcobendas, Rosa, Enriquez, Eugenia, Remesal, Agustin, de Inocencio, Jaime, Castro, Tania M., Lotufo, Simone A., Freye, Tatjana, Carlomagno, Raffaella, Zumbrunn, Thomas, Bonhoeffer, Jan, Schneider, Elvira Cannizzaro, Kaiser, Daniela, Hofer, Michaël, Hentgen, Véronique, Woerner, Andreas, Schwarz, Tobias, Klotsche, Jens, Niewerth, Martina, Ganser, Gerd, Jeyaratnam, Jerold, ter Haar, Nienke, Rigante, Donato, Dedeoglu, Fatma, Baris, Ezgi, Vastert, Sebastiaan, Frenkel, Joost, Lomax, Kathleen G., Shapiro, Ari, Durrant, Karen L., Brogan, P. A., Hofer, M., Kuemmerle-Deschner, J. B., Lauwerys, B., Speziale, A., Leon, K., Wei, X., Laxer, R. M., Signa, Sara, Rusmini, Marta, Campione, Elena, Chiesa, Sabrina, Grossi, Alice, Omenetti, Alessia, Caorsi, Roberta, Viglizzo, Gianmaria, Ceccherini, Isabella, Federici, Silvia, Lachmann, Helen, Ruperto, Nicola, Vanoni, Federica, Gomes, Sonia Melo, Omoyinmi, Ebun, Arostegui, Juan I., Gonzalez-Roca, Eva, Eleftheriou, Despina, Klein, Nigel, Brogan, Paul, Volpi, Stefano, Santori, Elettra, Picco, Paolo, Pastorino, Claudia, Rice, Gillian, Tesser, Alessandra, Crow, Yanick, Candotti, Fabio, Sinoplu, Ada B., Yucel, Gozde, Pamuk, Gizem, Damian, Laura O., Lazea, Cecilia, Sparchez, Mihaela, Vele, Paulina, Muntean, Laura, Albu, Adriana, Rednic, Simona, Lazar, Calin, Mendonça, Leonardo O., Pontillo, Alessandra, Kalil, Jorge, Castro, Fabio M., Barros, Myrthes T., Pardeo, Manuela, Messia, Virginia, De Benedetti, Fabrizio, Insalaco, Antonella, Malighetti, Giorgia, Gorio, Chiara, Ricci, Francesca, Parissenti, Ilaria, Montesano, Paola, Bonafini, Barbara, Medeghini, Veronica, Cattalini, Marco, Giordano, Lucio, Zani, Giulia, Ferraro, Rosalba, Vairo, Donatella, Giliani, Silvia, Maggio, Maria Cristina, Luppino, Girolamo, Corsello, Giovanni, Fernandez, Maria Isabel Gonzalez, Montesinos, Berta Lopez, Vidal, Adriana Rodriguez, Gorospe, Juan I. Arostegui, Penades, Inmaculada Calvo, Rafiq, Nadia K., Wynne, Karen, Hussain, Khalid, Brogan, Paul A., Ang, Elizabeth, Ng, Nicholas, Kacar, Ayla, Gucenmez, Ozge Altug, Makay, Balahan, Unsal, Sevket Erbil, Sahin, Yasin, Kutlu, Tufan, Cullu-Cokugras, Fugen, Ayyildiz-Civan, Hasret, Erkan, Tulay, Al Zuhbi, Sana, Abdalla, Eiman, Russo, Ricardo A., Katsicas, María M., Minoia, Francesca, Ravelli, Angelo, Bhattad, Sagar, Gupta, Anju, Pandiarajan, Vignesh, Nada, Ritambhra, Tiewsoh, Kaara, Hawkins, Philip, Rowczenio, Dorota, Fingerhutova, Sarka, Franova, Jana, Prochazkova, Leona, Hlavackova, Eva, Dolezalova, Pavla, Evrengül, Havva, Yüksel, Selçuk, Doğan, Mustafa, Gürses, Dolunay, Evrengül, Harun, De Pauli, Silvia, Pastore, Serena, Bianco, Anna Monica, Severini, Giovanni Maria, Taddio, Andrea, Tommasini, Alberto, Salugina, Svetlana O., Fedorov, Evgeny, Kamenets, Elena, Zaharova, Ekaterina, Sleptsova, Tatiana, Alexeeva, Ekaterina, Savostyanov, Kirill, Pushkov, Alexander, Bzarova, Tatyana, Valieva, Saniya, Denisova, Rina, Isayeva, Kseniya, Chistyakova, Evgeniya, Soloshenko, Margarita, Kaschenko, Elena, Kaneko, Utako, Imai, Chihaya, Saitoh, Akihiko, Teixeira, Vitor A., Ramos, Filipa O., Costa, Manuela, Aviel, Yonatan Butbul, Fahoum, Shafe, Brik, Riva, Özçakar, Zeynep Birsin, Celikel, Banu Acar, Yalcinkaya, Fatos, Schiappapietra, Benedetta, Davi’, Sergio, Mongini, Federica, Giannone, Luisa, Bava, Cecilia, Alpigiani, Maria Giannina, Consolaro, Alessandro, Lazarevic, Dragana S., Vojinovic, Jelena, Basic, Jelena, Muratore, Valentina, Marzetti, Valentina, Quilis, Neus, Benavente, Belen Serrano, Alongi, Alessandra, Civino, Adele, Quartulli, Lorenzo, Januskeviciute, Giedre, van Dijkhuizen, Pieter, Groot, N., van Dijk, W., Kardolus, A., Suárez, Raul Gutiérrez, Nordal, Ellen B., Rypdal, Veronika G., Berntson, Lillemor, Ekelund, Maria, Aalto, Kristiina, Peltoniemi, Suvi, Zak, Marek, Glerup, Mia, Arnstad, Ellen D., Fasth, Anders, Rygg, Marite, Duarte, Ana Catarina, Sousa, Sandra, Teixeira, Lídia, Cordeiro, Ana, Santos, Mª José, Mourão, Ana Filipa, Santos, Maria José, Eusébio, Mónica, Lopes, Ana, Oliveira-Ramos, Filipa, Salgado, Manuel, Estanqueiro, Paula, Melo-Gomes, José, Martins, Fernando, Costa, José, Furtado, Carolina, Figueira, Ricardo, Branco, Jaime C., Fonseca, João E., Canhão, Helena, Mourão, Ana F., Santos, Maria Jose, Coda, Andrea, Cassidy, Samuel, West, Kerry, Hendry, Gordon, Grech, Debra, Jones, Julie, Hawke, Fiona, Grewal, Davinder Singh, Foley, Charlene, Killeen, Orla, MacDermott, Emma, Veale, Douglas, Fearon, Ursula, Konukbay, Dilek, Tarakci, Ela, Arman, Nilay, Şahin, Sezgin, Munro, Jane, Morgan, Esi, Riebschleger, Meredith, Horonjeff, Jennifer, Strand, Vibeke, Bingham, Clifton, Collante, Ma. Theresa M., Ganeva, Margarita, Stefanov, Stefan, Telcharova, Albena, Mihaylova, Dimitrina, Saraeva, Radoslava, Tzveova, Reni, Kaneva, Radka, Tsakova, Adelina, Temelkova, Katya, Picarelli, Maria Mercedes C., Danzmann, Luiz C., Barbé-Tuana, Florencia, Grun, Lucas K., Jones, Marcus H., Frković, Marijan, Ištuk, Karla, Birkić, Ika, Sršen, Saša, Jelušić, Marija, Easton, Alan, Quarmby, Rachael, Khubchandani, Raju, Chan, Mercedes, Srp, Radoslav, Kobrova, Katerina, Nemcova, Dana, Hoza, Jozef, Uher, Michal, Saifridova, Melania, Linkova, Lenka, Charuvanij, Sirirat, Leelayuwattanakul, Isree, Pacharapakornpong, Thita, Vallipakorn, Sakda A.-O., Lerkvaleekul, Butsabong, Vilaiyuk, Soamarat, Lanni, Stefano, Davì, Sergio, Cron, Randy Q., Passarelli, Chiara, Pisaneschi, Elisa, Novelli, Antonio, Bracaglia, Claudia, Caiello, Ivan, de Graaf, Kathy, Guilhot, Florence, Ferlin, Walter, Schulert, Grant, Grom, Alexi A., Nelson, Robert, de Min, Cristina, Holzinger, Dirk, Kessel, Christoph, Fall, Ndate, Grom, Alexei, de Jager, Wilco, Strippoli, Raffaele, Horne, Anna, Ehl, Stephan, Ammann, Sandra, Lehmberg, Kai, Beutel, Karin, Foell, Dirk, Horne, AnnaCarin, Pagani, Laura, Espada, Graciela, Gao, Yi-jin, Shenoi, Susan, Weitzman, Sheila, Prencipe, Giusi, Pascarella, Antonia, Ferlin, Walter G., Chatel, Laurence, Jacqmin, Philippe, De Graaf, Kathy, Ballabio, Maria, Johnson, Zoë, Lapeyre, Geneviève, de Benedetti, Fabrizio, Cristina, de Min, Wakiguchi, Hiroyuki, Hasegawa, Shunji, Hirano, Reiji, Okazaki, Fumiko, Nakamura, Tamaki, Kaneyasu, Hidenobu, Ohga, Shouichi, Yamazaki, Kazuko, Nozawa, Tomo, Kanetaka, Taichi, Ito, Shuichi, Yokota, Shumpei, McLellan, Kirsty, MacGregor, Ishbel, Martin, Neil, Davidson, Joyce, Hansmann, Sandra, Eikelberg, Andreas, Haug, Iris, Schuller, Sabrina, Benseler, Susanne M., Nazarova, Liliia S., Danilko, Kseniia V., Malievsky, Viktor A., Viktorova, Tatiana V., Mauro, Angela, Barnicoat, Angela, Hurst, Jane, Canham, Nathalie, Lacassagne, Sandrine, Wiener, Anastasia, Hügle, Boris, Denecke, Bernd, Costa-Filho, Ivan, Haas, Johannes Peter, Tenbrock, Klaus, Popp, David, Boltjes, Arjan, Rühle, Frank, Herresthal, Stefanie, van Wijk, Femke, Schultze, Joachim, Stoll, Monika, Klotz, Luisa, Vogl, Thomas, Roth, Johannes, Quesada-Masachs, Estefania, de la Sierra, Daniel Álvarez, Prat, Marina Garcia, Sánchez, Ana M. Marín, Borrell, Ricardo Pujol, Barril, Sara Marsal, Gallo, Mónica Martínez, Caballero, Consuelo Modesto, Chyzheuskaya, Iryna, Byelyaeva, Lyudmyla M., Filonovich, Rostislav M., Khrustaleva, Helena K., Zajtseva, Larisa I., Yuraga, Tamara M., Giner, Thomas, Hackl, Lukas, Albrecht, Julia, Würzner, Reinhard, Brunner, Juergen, Minute, Marta, Parentin, Fulvio, Nocerino, Agostino, Nørgaard, Mette, Alberdi-Saugstrup, Mikel, Zak, Marek S., Nielsen, Susan M., Nordal, Ellen, Müller, Klaus G., Avramovič, Mojca Zajc, Dolžan, Vita, Toplak, Nataša, Avčin, Tadej, Ruperto, N., Lovell, D. J., Wallace, C., Toth, M., Foeldvari, I., Bohnsack, J., Milojevic, D., Rabinovich, C., Kingsbury, D., Marzan, K., Quartier, P., Minden, K., Chalom, E., Horneff, G., Kuester, R. M., Dare, J., Heinrich, M., Kupper, H., Kalabic, J., Brunner, H. I., Burgos-Vargas, Ruben, Constantin, Tamas, Dehoorne, Joke, Stanevica, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Mouy, Richard, Rumba-Rozenfelde, Ingrida, Job-Deslandre, Chantal, Pederson, Ronald, Bukowski, Jack, Hinnershitz, Tina, Vlahos, Bonnie, Keskitalo, Paula, Kangas, Salla, Vähäsalo, Paula, Valencia, Raul A. Chavez, Martino, David, Ponsonby, Anne-Louise, Chiaroni-Clarke, Rachel, Meyer, Braydon, Allen, Roger C., Akikusa, Jonathan D., Craig, Jeffrey M., Saffrey, Richard, Ellis, Justine A., Wallace, Carol, Uziel, Yosef, Sterba, Gary, Schneider, Rayfel, Russo, Ricardo, Ramanan, Athimalaipet V., Schmid, Jana Pachlopnik, Nichols, Kim E, Miettunen, Paivi, Kitoh, Toshiyuki, Ilowite, Norman T., Henter, Jan-Inge, Grom, Alexei A, Behrens, Edward M., Avcin, Tadej, Aricò, Maurizio, Grevich, Sriharsha, Lee, Peggy, Ringold, Sarah, Leroux, Brian, Leahey, Hannah, Yuasa, Megan, Foster, Jessica, Sokolove, Jeremy, Lahey, Lauren, Robinson, William, Newson, Joshua, Stevens, Anne, Shoop, Stephanie J. W., Verstappen, Suzanne M. M., Thomson, Wendy, McDonagh, Janet E., Beukelman, Timothy, Kimura, Yuki, Natter, Marc, Ilowite, Norm, Mieszkalski, Kelly, Burrell, Grendel, Best, Brian, Bristow, Helen, Carr, Shannon, Dennos, Anne, Kaufmann, Rachel, Schanberg, Laura, Simonini, Gabriele, Lancini, Francesca, Gerbaux, Margaux, Lê, Phu-Quoc, Goffin, Laurence, Badot, Valérie, La, Céline, Caspers, Laure, Willermain, François, Ferster, Alina, Ceci, Maria, Licciardi, Francesco, Turco, Marco, Santarelli, Francesca, Montin, Davide, Toppino, Claudia, Alizzi, Clotilde, Papia, Bruno, Vergara, Beatrice, Corpora, Umberto, Messina, Luca, Tsinti, Maria, Dermentzoglou, Vasiliko, Tziavas, Panagiotis, Perica, Marija, Bukovac, Lana Tambić, Çakan, Mustafa, Ayaz, Nuray Aktay, Keskindemirci, Gonca, Lang, Michael, Laing, Catherine, Benseler, Susanne, Gerschman, Tommy, Luca, Nadia, Schmeling, Heinrike, Dropol, Anastasia, Taiani, Jaymi, Johnson, Nicole, Rusted, Brian, Nalbanti, Panagiota, Pratsidou, Polyxeni, Pardalos, Grigoris, Tzimouli, Vasiliki, Taparkou, Anna, Stavrakidou, Maria, Papachristou, Fotios, Kanakoudi-Tsakalidou, Florence, Bale, Peter, Robinson, Emily, Palman, Jason, Ralph, Elizabeth, Gilmour, Kimberly, Heard, Clare, Wedderburn, Lucy R., Barrense-Dias, Yara, Gregory, Antonarakis, Amira, Dhouib, Paolo, Scolozzi, Sylviane, Hanquinet, Michaël, Hofer, Panko, Nataliya, Shokry, Salah, Rakovska, Liudmila, Pino, Sally, Diaz-Maldonado, Adriana, Guarnizo, Pilar, Torreggiani, Sofia, Cressoni, Paolo, Garagiola, Umberto, Di Landro, Giancarla, Farronato, Giampietro, Corona, Fabrizia, Bell, Samantha, Bhatti, Parveen, Nelson, Lee, Mueller, Beth A., Simon, T. A., Baheti, A., Ray, N., Guo, Z., Hazra, Anasuya, Stock, Thomas, Wang, Ronnie, Mebus, Charles, Alvey, Christine, Lamba, Manisha, Krishnaswami, Sriram, Conte, Umberto, Wang, Min, Kingsbury, Daniel, Koskova, Elena, Smolewska, Elzbieta, Vehe, Richard K., Lovell, Daniel, Kubota, Tomohiro, Yasumura, Junko, Kizawa, Toshitaka, Yashiro, Masato, Yamatou, Tsuyoshi, Yamasaki, Yuichi, Takei, Syuji, Kawano, Yoshifumi, Nykvist, Ulrika Järpemo, Magnusson, Bo, Wicksell, Rikard, Palmblad, Karin, Olsson, Gunnar L., Modaressi, Mohammadreza, Moradinejad, Mohammad-Hassan, Seraya, Valentina, Vitebskaya, Alisa, Moshe, Veronica, Amarilyo, Gil, Harel, Liora, Hashkes, Phillip J, Mendelson, Amir, Rabinowicz, Noa, Reis, Yonit, Dāvidsone, Zane, Lazareva, Arina, Šantere, Ruta, Bērziņa, Dace, Staņēviča, Valda, Varnier, Giulia Camilla, Maillard, Susan, Ferrari, Cristina, Zaffarano, Silvia, Wienke, Judith, Enders, Felicitas Bellutti, van den Hoogen, Lucas L., Mertens, Jorre S., Radstake, Timothy R., Hotten, Henny G., Fritsch, Ruth, Wedderburn, Lucy, Nistala, Kiran, Prakken, Berent, van Royen-Kerkhof, Annet, Alhemairi, Mohammad, Muzaffer, Mohammed, Van Dijkhuizen, Pieter, Deakin, Claire T., Simou, Stefania, De Iorio, Maria, Wu, Qiong, Amin, Tania, Dossetter, Lee, Campanilho-Marques, Raquel, Deakin, Claire, Pilkington, Clarissa A., Rosina, Silvia, Soponkanaporn, Sirisucha, Arıcı, Zehra S., Tuğcu, Gökçen D., Batu, Ezgi D., Sönmez, Hafize E., Doğru-Ersöz, Deniz, Talim, Beril, Kiper, Nural, Özen, Seza, Solyom, Alexander, Batu, Ezgi, Mitchell, John, Kariminejad, Ariana, Hadipour, Fatemeh, Hadipour, Zahra, Torcoletti, Marta, Agostoni, Carlo, Di Rocco, Maja, Tanpaiboon, Pranoot, Superti-Furga, Andrea, Bonafé, Luisa, Arslan, Nur, Guelbert, Norberto, Ehlert, Karoline, Grigelioniene, Giedre, Puri, Ratna, Schuchman, Edward, Gomez, Pilar, Gonzalez, Tatiana, Yepez, Ricardo, Vargas, Camilo, Fernanda, Falcini, Lepri, Gemma, Ferrari, Alessandra, Matucci-Cerinic, Marco, Meini, Antonella, Moneta, Gian Marco, Marasco, Emiliano, Nicolai, Rebecca, Bracci-Laudiero, Luisa, Kopchak, Olga, Mushkin, Alexander, Maletin, Alexey, Mosquera, Catalina, Amorim, Rita A., Molina, Juliana, Moreira, Gustavo, Santos, Flávia H., Fraga, Melissa, Keppeke, Livia, Silva, Vanessa M., Hirotsu, Camila, Tufik, Sergio, Terreri, Maria Teresa, Braga, Vinícius L., Fonseca, Maria Beatriz, Schinzel, Vania, Terreri, Maria Teresa R., Jorge, Liliana, Guerra, Liana, Junior, Edson Amaro, Castiglione, Maria Cristina, Tricarico, Alessandra, Boulter, Emily, Schultz, Andre, Murray, Kevin, Falcini, Fernanda, Stagi, Stefano, Bellucci, Eleonora, Grein, Ingrid H. R., Pileggi, Gecilmara, Pinto, Natália B. F., de Oliveira, Aline L., Belyaeva, Lyudmila, Filonovich, Rostislav, Khrustaleva, Helena, Zajtseva, Larisa, Ilisson, Jaanika, Pruunsild, Chris, Gilliaux, Olivier, Corazza, Francis, Lelubre, Christophe, Morel, Zoilo, C, Claudia Saad-Magalhães, Lira, Luis, Ladino, Mabel, Eraso, Ruth, Arroyo, Ivonne, Silva, Clovis, Rose, Carlos, and Hausmann, Jonathan

Abstract

Version of Record

Published
2017
Full Text
View/download PDF

89. Clinical Characteristics of Children With Juvenile Dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry.

Author

Robinson, Angela Byun, Hoeltzel, Mark F., Wahezi, Dawn M., Becker, Mara L., Kessler, Elizabeth A., Schmeling, Heinrike, Carrasco, Ruy, Huber, Adam M., Feldman, Brian M., and Reed, Ann M.

Abstract

Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

90. Influence of Methylenetetrahydrofolate Reductase Polymorphisms on Efficacy and Toxicity of Methotrexate in Patients with Juvenile Idiopathic Arthritis

Author

Schmeling, Heinrike, Biber, Daniel, Heins, Sigrid, and Horneff, Gerd

Abstract

OBJECTIVE: To study the relationship of C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene to toxicity and efficacy of methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA). METHODS: Single nucleotide polymorphisms of the MTHFR gene were investigated by polymerase chain reaction and restriction enzyme analysis of DNA extracted from peripheral blood cells. The fasting plasma homocysteine concentration was analyzed by enzyme immunoassay. Clinical data of 58 patients with JIA treated with MTX were analyzed retrospectively. RESULTS: The 1298A/A genotype was present in 31 patients, 1298C/C in 4 patients, and 21 patients were heterozygous. The 677C/C genotype was present in 29 patients, 677 T/T in 3 patients, and 26 patients were heterozygous. In patients who presented the C allele of the A1298C polymorphism, improvement with respect to the number of swollen joints, the number of tender joints, and a decrease in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels occurred more frequently than in 1298 A/A homozygous patients (p < 0.05 for ESR, p < 0.01 for CRP, chi-square test). There was no relationship between the C677T polymorphism and the efficacy of MTX treatment. Forty-two adverse events were noted in 26 patients; gastrointestinal symptoms were most common (n = 20), followed by elevated serum levels of transaminases (n = 19) and hair loss (n = 3). There was no cytopenia. Patients with the heterozygous genotype 677C/T exhibited adverse events more frequently than patients with the homozygous C/C genotype (65% vs 31%; p < 0.05, chi-square test). The A1298C polymorphism, however, was not associated with occurrence of adverse events. Plasma homocysteine was elevated in 6 patients with up to 16.9 mmol/l. No association was found to a specific genotype or to adverse events. CONCLUSION: These preliminary data suggest an association of the MTHFR 677C/C polymorphism to a higher tolerability of MTX, and of the 1298A/A to lower clinical efficacy of MTX therapy in JIA.

Published
2005

91. Clinical/Scientific Notes.

Author

Mineyko, Aleksandra, Narendran, Aru, Fritzler, Mark L., Xing-Chang Wei, Schmeling, Heinrike, and Kirton, Adam

Published
2012

93. Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Author

Guzman, Jaime, Kerr, Tristan, Ward, Leanne M, Ma, Jinhui, Oen, Kiem, Rosenberg, Alan M, Feldman, Brian M, Boire, Gilles, Houghton, Kristin, Dancey, Paul, Scuccimarri, Rosie, Bruns, Alessandra, Huber, Adam M, Watanabe Duffy, Karen, Shiff, Natalie J, Berard, Roberta A, Levy, Deborah M, Stringer, Elizabeth, Morishita, Kimberly, Johnson, Nicole, Cabral, David A, Larché, Maggie, Petty, Ross E, Laxer, Ronald M, Silverman, Earl, Miettunen, Paivi, Chetaille, Anne-Laure, Haddad, Elie, Spiegel, Lynn, Turvey, Stuart E, Schmeling, Heinrike, Lang, Bianca, Ellsworth, Janet, Ramsey, Suzanne E, Roth, Johannes, Campillo, Sarah, Benseler, Susanne, Chédeville, Gaëlle, Schneider, Rayfel, Tse, Shirley M L, Bolaria, Roxana, Gross, Katherine, Feldman, Debbie, Cameron, Bonnie, Jurencak, Roman, Dorval, Jean, LeBlanc, Claire, St. Cyr, Claire, Gibbon, Michele, Yeung, Rae S M, Duffy, Ciarán M, and Tucker, Lori B

Subjects
2. Zero hunger
Abstract

Background: With modern treatments, the effect of juvenile idiopathic arthritis (JIA) on growth may be less than previously reported. Our objective was to describe height, weight and body mass index (BMI) development in a contemporary JIA inception cohort. Methods: Canadian children newly-diagnosed with JIA 2005–2010 had weight and height measurements every 6 months for 2 years, then yearly up to 5 years. These measurements were used to calculate mean age- and sex-standardized Z-scores, and estimate prevalence and cumulative incidence of growth impairments, and the impact of disease activity and corticosteroids on growth. Results: One thousand one hundred forty seven children were followed for median 35.5 months. Mean Z-scores, and the point prevalence of short stature (height < 2.5th percentile, 2.5% to 3.4%) and obesity (BMI > 95th percentile, 15.8% to 16.4%) remained unchanged in the whole cohort. Thirty-three children (2.9%) developed new-onset short stature, while 27 (2.4%) developed tall stature (>97.5th percentile). Children with systemic arthritis (n = 77) had an estimated 3-year cumulative incidence of 9.3% (95%CI: 4.3–19.7) for new-onset short stature and 34.4% (23–49.4) for obesity. Most children (81.7%) received no systemic corticosteroids, but 1 mg/Kg/day prednisone-equivalent maintained for 6 months corresponded to a drop of 0.64 height Z-scores (0.56–0.82) and an increase of 0.74 BMI Z-scores (0.56–0.92). An increase of 1 in the 10-cm physician global assessment of disease activity maintained for 6 months corresponded to a drop of 0.01 height Z-scores (0–0.02). Conclusions: Most children in this modern JIA cohort grew and gained weight as children in the general population. About 1 in 10 children who had systemic arthritis, uncontrolled disease and/or prolonged corticosteroid use, had increased risk of growth impairment.

94. IDENTIFICATION OF OPTIMAL SUBCUTANEOUS DOSES OF TOCILIZUMAB IN CHILDREN WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS

Author

Brunner, Hermine I., Ruperto, Nicola, Martini, Alberto, Ramanan, Athimalaipet V., Cuttica, Ruben, Weiss, Jennifer E., Henrickson, Michael, Schmeling, Heinrike, Anton, Jordi, Minden, Kirsten, Hsu, Joy, Bharucha, Kamal, Wimalasundera, Sunethra, Kadva, Alysha K., Upmanyu, Ruchi, Mallalieu, Navita L., Douglass, Wendy, Lovell, Daniel J., and fabrizio De Benedetti

95. A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry.

Author

Nguyen K, Barsalou J, Basodan D, Batthish M, Benseler SM, Berard RA, Blanchette N, Boire G, Bolaria R, Bruns A, Cabral DA, Cameron B, Campillo S, Cellucci T, Chan M, Chédeville G, Chetaille AL, Chhabra A, Couture J, Dancey P, De Bruycker JJ, Demirkaya E, Dhalla M, Duffy CM, Feldman BM, Feldman DE, Gerschman T, Haddad E, Heale L, Herrington J, Houghton K, Huber AM, Human A, Johnson N, Jurencak R, Lang B, Larché M, Laxer RM, LeBlanc CM, Lee JJY, Levy DM, Lim L, Lim LSH, Luca N, McGrath T, McMillan T, Miettunen PM, Morishita KA, Ng HY, Oen K, Park J, Petty RE, Proulx-Gauthier JP, Ramsey S, Roth J, Rosenberg AM, Rozenblyum E, Rumsey DG, Schmeling H, Schneider R, Scuccimarri R, Shiff NJ, Silverman E, Soon G, Spiegel L, Stringer E, Tam H, Tse SM, Tucker LB, Turvey S, Twilt M, Duffy KW, Yeung RSM, and Guzman J

Subjects
Humans, Canada epidemiology, Male, Female, Child, Treatment Outcome, Adolescent, Child, Preschool, Biological Products therapeutic use, Severity of Illness Index, Arthritis, Juvenile drug therapy, Registries, Antirheumatic Agents therapeutic use
Abstract

Objective: To assess changes in juvenile idiopathic arthritis (JIA) treatments and outcomes in Canada, comparing 2005-2010 and 2017-2021 inception cohorts., Methods: Patients enrolled within three months of diagnosis in the Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) and the Canadian Alliance of Pediatric Rheumatology Investigators Registry (CAPRI) cohorts were included. Cumulative incidences of drug starts and outcome attainment within 70 weeks of diagnosis were compared with Kaplan-Meier survival analysis and multivariable Cox regression., Results: The 2005-2010 and 2017-2021 cohorts included 1128 and 721 patients, respectively. JIA category distribution and baseline clinical juvenile idiopathic arthritis disease activity (cJADAS10) scores at enrolment were comparable. By 70 weeks, 6% of patients (95% CI 5, 7) in the 2005-2010 and 26% (23, 30) in the 2017-2021 cohort had started a biologic DMARD (bDMARD), and 43% (40, 47) and 60% (56, 64) had started a conventional DMARD (cDMARD), respectively. Outcome attainment was 64% (61, 67) and 83% (80, 86) for inactive disease (Wallace criteria), 69% (66, 72) and 84% (81, 87) for minimally active disease (cJADAS10 criteria), 57% (54, 61) and 63% (59, 68) for pain control (<1/10), and 52% (47, 56) and 54% (48, 60) for good health-related quality of life (≥9/10)., Conclusion: Although baseline disease characteristics were comparable in the 2005-2010 and 2017-2021 cohorts, cDMARD and bDMARD use increased with a concurrent increase in minimally active and inactive disease. Improvements in parent and patient-reported outcomes were smaller than improvements in disease activity., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

96. Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis.

Author

Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, Lee JJY, Feldman BM, Berard RA, Dancey P, Huber AM, Scuccimarri R, Cabral DA, Morishita KA, Ramsey SE, Rosenberg AM, Boire G, Benseler SM, Lang B, Houghton K, Miettunen PM, Chédeville G, Levy DM, Bruns A, Schmeling H, Haddad E, Yeung RSM, and Duffy CM

Subjects
Adolescent, Adolescent Development, Age Factors, Arthritis, Juvenile physiopathology, Arthritis, Juvenile therapy, Canada, Child, Child Development, Child, Preschool, Disability Evaluation, Female, Humans, Longitudinal Studies, Male, Pain Measurement, Predictive Value of Tests, Prognosis, Time Factors, Adolescent Behavior, Arthritis, Juvenile diagnosis, Arthritis, Juvenile psychology, Child Behavior, Quality of Life, Surveys and Questionnaires
Abstract

Objective: To describe changes in health-related quality of life (HRQoL) over time in children with juvenile idiopathic arthritis (JIA), relative to other outcomes, and to identify predictors of unfavorable HRQoL trajectories., Methods: Children with JIA in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) cohort were included. The Juvenile Arthritis Quality of Life Questionnaire (JAQQ, a standardized instrument), health-related Quality of My Life (HRQoML, an instrument based on personal valuations), and JIA core variables were completed serially. Analyses included median values, Kaplan-Meier survival curves, and latent trajectory analysis., Results: A total of 1,249 patients enrolled at a median of 0.5 months after diagnosis were followed for a median of 34.2 months. The degree of initial HRQoL impairment and probabilities of reaching the best possible HRQoL scores varied across JIA categories (best for oligoarthritis, worst for rheumatoid factor-positive polyarthritis). Median times to attain best possible HRQoL scores (JAQQ 59.3 months, HRQoML 34.5 months), lagged behind those for disease activity, pain, and disability measures. Most patients followed trajectories with minimal or mild impairment; however, 7.6% and 13.8% of patients, respectively, followed JAQQ and HRQoML trajectories with persistent major impairment in HRQoL. JIA category, aboriginal ethnicity, and baseline disease activity measures distinguished between membership in trajectories with major and minimal impairments., Conclusion: Improvement in HRQoL is slower than for disease activity, pain, and disability. Improvement of a measure based on respondents' preferences (HRQoML) is more rapid than that of a standardized measure (JAQQ). Higher disease activity at diagnosis heralds an unfavorable HRQoL trajectory., (© 2017, American College of Rheumatology.)

Published
2018
Full Text
View/download PDF

97. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Author

Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, and Wallace C

Subjects
Adolescent, Child, Child, Preschool, Dose-Response Relationship, Drug, Evidence-Based Medicine, Humans, Time Factors, Treatment Outcome, Dermatomyositis drug therapy, Practice Guidelines as Topic, Steroids therapeutic use
Abstract

Objective: To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment., Methods: A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion., Results: Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed., Conclusion: We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM., (Copyright © 2012 by the American College of Rheumatology.)

Published
2012
Full Text
View/download PDF

98. [Prader-Labhart-Willi syndrome in infants].

Author

Schmeling H, Gillessen-Kaesbach G, Schulte-Mattler U, Burdach S, and Horneff G

Subjects
Autoantigens genetics, Chromosomes, Human, Pair 15, Diagnosis, Differential, Humans, Infant, Infant, Newborn, Male, Neurologic Examination, Polymerase Chain Reaction, Prader-Willi Syndrome genetics, snRNP Core Proteins, Prader-Willi Syndrome diagnosis, Ribonucleoproteins, Small Nuclear
Abstract

We report an infant with severe hypotonia, feeding problems and failure to thrive in the neonatal period, followed by developmental delay. In addition, pale skin, eyelid and pedal edema, cryptorchidism and micrognathia were present. The tentative diagnosis of Prader-Labhart-Willi syndrome was made and confirmed by specific molecular testing at the age of 5 months. The Prader-Labhart-Willi syndrome is usually diagnosed in older infants when the main clinical features such as obesity, short stature, hypogonadism and developmental delay become obvious, in most of the patients typical clinical features are present already in the neonatal period. In conclusion, in neonates and young infants presenting with hypotonia and feeding problems, the Prader-Labhart-Willi syndrome should be considered.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results